Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT04459611 2022-07-12

neoSCORE

Phase 2 Unknown

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05008861 2021-08-17

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Phase 1 Unknown

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04846452 2021-08-12

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Phase 2 Unknown

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04612673 2020-11-03

A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC

Phase 2 Unknown

33 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03987867 2020-07-07

Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

Phase 1 Unknown

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04371796 2020-05-01

Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

Phase 2 Unknown

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

NCT04252365 2020-02-05

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

Phase 2 Unknown

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04106180 2019-09-26

SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC

Phase 2 Unknown

63 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03874000 2019-03-19

SMART

Phase 2 Unknown

43 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03765775 2018-12-06

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Phase 2 Unknown

20 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Clinical Trials

TRUMP

neoSCORE

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC

Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC

SMART

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative